{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-052704","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.465359+00:00","generated_at":"2026-05-20T10:57:26.850501+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioXcel Therapeutics granted Nasdaq listing extension to Sept 16, 2025","bullets":["Nasdaq Hearings Panel extended compliance deadline for MVLS Rule (minimum $35M market value for 10 consecutive days) to September 16, 2025.","Extension is subject to BioXcel meeting certain interim conditions set by the Panel.","Company previously faced potential delisting for failing to satisfy Nasdaq Listing Rule 5550(b)(2).","Decision follows review of BioXcel's compliance plan and strategies for long-term compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-052704","json":"https://secwatch.observer/filing/0001104659-25-052704.json","markdown":"https://secwatch.observer/filing/0001104659-25-052704.md","text":"https://secwatch.observer/filing/0001104659-25-052704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925052704/0001104659-25-052704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925052704/tm2516117d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:57:26.850501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}